c-MET EXPRESSION AS AN INDICATOR OF SURVIVAL OUTCOME IN PATIENTS WITH ORAL TONGUE CARCINOMA

被引:34
作者
Kim, Chul-Ho [2 ]
Koh, Yoon Woo [3 ]
Han, Jae Ho [4 ]
Kim, Jae Wook [3 ]
Lee, Jin Seok [2 ]
Baek, Seung Jae [5 ]
Hwang, Hye Sook [2 ]
Choi, Eun Chang [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul, South Korea
[2] Ajou Univ, Sch Med, Dept Otolaryngol, Suwon 441749, South Korea
[3] Soonchunhyang Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Puchon, South Korea
[4] Ajou Univ, Sch Med, Dept Pathol, Suwon 441749, South Korea
[5] Kwandong Univ, Coll Med, Dept Otorhinolaryngol, Koyang, South Korea
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2010年 / 32卷 / 12期
关键词
oral tongue cancer; hepatocyte growth factor (HGF); c-Met; prognosis; HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL-CARCINOMA; FACTOR-RECEPTOR; HYPOPHARYNGEAL CARCINOMA; SCATTER FACTOR; IN-VITRO; STAGE-I; METASTASIS; CANCER; HEAD;
D O I
10.1002/hed.21383
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Hepatocyte growth factor (HGF) can promote proliferation, invasion, and angiogenesis in various tumor cells. However, the prognosis according to expression of HGF/c-Met has not been reported in patients with squamous cell carcinoma of the oral tongue (SCOOT). Methods. Tumors from 61 patients with SCOOT were evaluated for the expression of HGF and c-Met by immunohistochemistry. For Western blot, we used fresh normal and cancer tissues from 3 patients with SCOOT. Results. The positive rates of HGF and c-Met immunostaining in SCOOT were 57.3% and 54.1%, respectively. The c-Met staining was significantly correlated with lymph node metastasis (p = .005), tumor classification (p = .004), and recurrence (p = .018). Survival was significantly affected in patients with positive c-Met expression (p = .003). HGF and c-Met were strongly expressed in cancer tissues on Western blot. Conclusion. The c-Met expression may play an important role in the progression and the survival outcome of patients with SCOOT. (C) 2010 Wiley Periodicals, Inc. Head Neck 32: 1655-1664, 2010
引用
收藏
页码:1655 / 1664
页数:10
相关论文
共 40 条
[1]  
Akervall J, 2004, CLIN CANCER RES, V10, P8204, DOI 10.1158/1078-0432.CCR-04-0722
[2]   Predictive factors of occult metastasis and prognosis of clinical stages I and II squamous cell carcinoma of the tongue and floor of the mouth [J].
Amaral, TMP ;
da Silva Freire, AR ;
Carvalho, AL ;
Pinto, CAL ;
Kowalski, LP .
ORAL ONCOLOGY, 2004, 40 (08) :780-786
[3]   DIFFERENTIAL TUBULOGENIC AND BRANCHING MORPHOGENETIC ACTIVITIES OF GROWTH-FACTORS - IMPLICATIONS FOR EPITHELIAL TISSUE-DEVELOPMENT [J].
BARROS, EJG ;
SANTOS, OFP ;
MATSUMOTO, K ;
NAKAMURA, T ;
NIGAM, SK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (10) :4412-4416
[4]   The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants [J].
Berthou, S ;
Aebersold, DM ;
Schmidt, LS ;
Stroka, D ;
Heigl, C ;
Streit, B ;
Stalder, D ;
Gruber, G ;
Liang, CX ;
Howlett, AR ;
Candinas, D ;
Greiner, RH ;
Lipson, KE ;
Zimmer, Y .
ONCOGENE, 2004, 23 (31) :5387-5393
[5]   Met provides essential signals for liver regeneration [J].
Borowiak, M ;
Garratt, AN ;
Wüstefeld, T ;
Strehle, M ;
Trautwein, C ;
Birchmeier, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (29) :10608-10613
[6]   IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT [J].
BOTTARO, DP ;
RUBIN, JS ;
FALETTO, DL ;
CHAN, AML ;
KMIECIK, TE ;
VANDEWOUDE, GF ;
AARONSON, SA .
SCIENCE, 1991, 251 (4995) :802-804
[7]  
Christensen JG, 2003, CANCER RES, V63, P7345
[8]   Cancer therapy: can the challenge be MET? [J].
Corso, S ;
Comoglio, PM ;
Giordano, S .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (06) :284-292
[9]   Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas [J].
Di Renzo, MF ;
Olivero, M ;
Martone, T ;
Maffe, A ;
Maggiora, P ;
De Stefani, A ;
Valente, G ;
Giordano, S ;
Cortesina, G ;
Comoglio, PM .
ONCOGENE, 2000, 19 (12) :1547-1555
[10]  
DIRENZO MF, 1995, CANCER RES, V55, P1129